35122-96-4

Basic information

• Product Name: 3,5-DIIODOANILINE
• Synonyms: 3,5-DIIODOANILINE;3,5-DIIODOBENZENAMINE
• CAS NO: 35122-96-4
• Molecular Formula: C₆H₅I₂N
• Molecular Weight: 344.92
• Mol File: 35122-96-4.mol

Chemical Properties

• Appearance: /
• PKA: pK1:2.37(+1) (25°C)
• CAS DataBase Reference: 3,5-DIIODOANILINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-DIIODOANILINE(35122-96-4)
• EPA Substance Registry System: 3,5-DIIODOANILINE(35122-96-4)

Safety Data

• Hazardous Substances Data: 35122-96-4(Hazardous Substances Data)

Usage

Uses

Used in Chemical Synthesis:
3,5-Diiodoaniline is used as a reactant for the preparation of triiodobenzene, which is an essential intermediate in the synthesis of phenylacetylene-based conjugated dendrimers with unsymmetrical branching. These dendrimers have potential applications in various fields, such as materials science, electronics, and pharmaceuticals, due to their unique structural and electronic properties.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 3,5-diiodoaniline can be used as a starting material for the synthesis of various iodinated drugs and contrast agents. The presence of iodine atoms in the molecule enhances its reactivity and allows for the formation of new compounds with potential therapeutic applications.
Used in Research and Development:
3,5-Diiodoaniline is also utilized in research and development for the study of chemical reactions and the development of new synthetic methods. Its unique reactivity and structural features make it an interesting compound for exploring new reaction pathways and understanding the underlying mechanisms.

Upstream product

• 57830-60-1 3,5-diiodonitrobenzene 
• 53663-23-3 1,2,3-triiodo-5-nitrobenzene 
• 116529-49-8 2,4-diiodo-6-nitroaniline 
• 88-74-4 2-nitro-aniline 
• 100-01-6 4-nitro-aniline 
• 5398-27-6 2,6-diiodo-4-nitroaniline 

Downstream Products

• 6286-37-9 acetic acid-(3,5-diiodo-anilide) 
• 20981-79-7 3,5-diiodophenol 
• 852944-56-0 N,N-dihexyl-3,5-diiodoaniline 
• 954105-35-2 1-(3,5-diiodophenyl)-3,3-diethyltriaz-1-ene 
• 1248386-96-0 3,5-bis(pyridine-4-ylethynyl)aniline 
• 402956-36-9 3,5-diethynylaniline 
• 57598-13-7 3,5-diiodobenzenesulfonyl chloride 
• 149833-45-4 3,5-diiodophenyldiazonium hexafluorophosphate 
• 350589-43-4 3,5-bis-[2-(2,5-dipropyloxy-4-{2-[3-(tetrahydro-2H-pyran-2-yloxy)-5-(2-trimethylsilylethynyl)phenyl]ethynyl}phenyl)ethynyl]toluene 
• 350589-39-8 3,5-bis-[2-(2,5-dipropyloxy-4-{2-[5-iod-3-(tetrahydro-2H-pyran-2-yloxy)phenyl]ethynyl}phenyl)ethynyl]toluene 

Relevant articles and documents

Halogen bonding-enhanced electrochemical halide anion sensing by redox-active ferrocene receptors

The first examples of halogen bonding redox-active ferrocene receptors and their anion electrochemical sensing properties are reported. Halogen bonding was found to significantly amplify the magnitude of the receptor's metallocene redox-couple's voltammet

Reduction-rebridging strategy for the preparation of ADPN-based antibody-drug conjugates

The reduction-rebridging strategy is a powerful method for the preparation of stable and homogeneous antibody-drug conjugates (ADCs). In this communication, we describe the development of the arylene-dipropiolonitrile (ADPN) functional group for the rebri

3,5-diiodo benzenesulfonyl choride preparation technology

The invention discloses a 3,5-diiodo benzenesulfonyl choride preparation technology. The preparation technology comprises the following steps: taking paranitroaniline as a raw material, performing a substitution reaction to generate 2,6-diiodo-4-nitro aniline, performing diazotization and hydrolysis on 2,6-diiodo-4-nitro aniline and performing hydrolysis to generate 3,5-diodonitrobenzene, performing a reduction reaction on the 3,5-diodonitrobenzene to generate 3,5-diiodoaniline, performing diazotization and a sulfonylation reaction on the 3,5-diiodoaniline to obtain a target compound 3,5-diiodo benzenesulfonyl choride. The technology has the advantages of easily available raw materials, simple operation and post-treatment, and high yield, and is suitable for industrial production.

MICROBUBBLE-CHEMOTHERAPEUTIC AGENT COMPLEX FOR SONODYNAMIC THERAPY

The invention relates to methods of sonodynamic therapy comprising the co-administration of a microbubble-chemotherapeutic agent complex together with a microbubble-sonosensitiser complex. It further relates to pharmaceutical compositions comprising these

A Pronounced Halogen Effect on the Organogelation Properties of Peripherally Halogen Functionalized Poly(benzyl ether) Dendrons

An interesting halogen-substituent effect on the organogelation properties of poly(benzyl ether) dendrons is reported. A new class of poly(benzyl ether) dendrons with halo substituents decorating their periphery was synthesized and fully characterized. A

Synthesis and optoelectronic properties of janus -dendrimer-type multivalent donor-acceptor systems

A convergent, multistep protocol was employed for the synthesis of a Janus-type multivalent donor-acceptor system. The synthetic approach is based on a Sonogashira cross-coupling of two differently ferrocene-(Fc) substituted dendrons and a final sixfold [

Iron(III) complexes with meta-substituted bis(arylimino)pyridine ligands: Catalyst precursors for the selective oligomerization of ethylene

Bis(arylimino)pyridine iron(III) complexes containing meta-halogen substituents at the iminophenyl rings were synthesized and characterized. In contrast to iron(II) complexes, the presence of at least one ortho-substituent at the iminophenyl rings is not obligative for catalytic activities of these iron(III) complexes. After activation with methylaluminoxane (MAO), these catalysts oligomerize ethylene to give also internal and branched olefins besides the expected linear α-olefins. The widths of the resulting molecular weight distributions and the degrees of isomerization of the resulting oligomers strongly depend on the substitution pattern at the ligand frameworks.

Leukotriene B4 Inhibitors

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, COPD

ANTIBACTERIAL COMPOSITIONS

Compounds of formula (I) have antibacterial activity: wherein: m is 0 or 1 ; Q is hydrogen or cyclopropyl; AIk is an optionally substituted, divalent C1-C6 alkylene, alkenylene or alkynylene radical which may contain an ether (-O-), thioether (-S-) or amino (-NR)- link, wherein R is hydrogen, -CN or C1-C3 alkyl; X is -C(=O)NR6-, -S(O)NR6-, -C(=O)O- or -S(=O)O- wherein R6 is hydrogen, optionally substituted C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, -Cyc, or -( C1-C3 alkyl)-Cyc wherein Cyc is optionally substituted monocyclic carbocyclic or heterocyclic having 3-7 ring atoms; Z is N or CH, or CF; R2 and R3 are as defined in the description.

Synthesis of new diethynylbenzene derivatives

The preparation of new monomeric diacetylenic aromatic compounds is described.